E. Kraynov

发表

A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics

P. Vicini, T. Hickling, Xiaoying Chen, 2013, The AAPS Journal.

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

S. Hu-Lieskovan, S. Salek-Ardakani, P. Declerck, 2019, Journal of Immunotherapy for Cancer.

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

M. Dorywalska, A. Rajpal, J. Pons, 2016, Molecular Cancer Therapeutics.

A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition

E. Kraynov, S. Bergqvist, D. Hu-Lowe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Evolutionarily Conserved Wnk and Ste20 Kinases Are Essential for Acute Volume Recovery and Survival after Kinase to Regulate P21waf1/cip1 Stability Mst Kinases Monitor Actin Cytoskeletal Integrity and Signal via C-jun N-terminal Kinase Stress-activated Small-molecule P21-activated Kinase Inhibitor P

J. Lamerdin, W. Kolch, J. Christensen, 2006 .

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010, Clinical Cancer Research.

Fully Human Monoclonal Antibody against R adherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010 .

Abstract 3485: Inhibition of Notch signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells

P. Wei, Jennifer Yang, G. Han, 2012 .

Receptor occupancy and blocking of STAT5 signaling by an anti‐IL‐7 receptor α antibody in cynomolgus monkeys

E. Kraynov, Li-Fen Lee, W. Li, 2016, Cytometry. Part B, Clinical cytometry.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper

D. Rock, Michaela Bairlein, A. Kamath, 2016, Drug Metabolism and Disposition.

Use of Animal Models for Projection of Clinical Drug–Drug Interactions for Therapeutic Proteins

M. Dowty, E. Kraynov, 2013 .

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

J. Chaparro-Riggers, L. Aschenbrenner, P. Strop, 2019, Scientific Reports.

Structure-based design of novel human Pin1 inhibitors (II).

J. Thomson, S. Greasley, E. Kraynov, 2010, Bioorganic & medicinal chemistry letters.

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential

Steven W. Martin, M. Dowty, E. Kraynov, 2011, Drug Metabolism and Disposition.

Biological Characterization of a Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GnRH) Antagonist Using Castrated and Intact Rats

Mark B. Anderson, G. Paderes, D. Luthin, 2003, Journal of Pharmacology and Experimental Therapeutics.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

P. O'Connor, A. Blasina, J. Register, 2008, Molecular Cancer Therapeutics.

Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket.

Genevieve D Paderes, Samantha Greasley, Eugenia Kraynov, 2014, Bioorganic & medicinal chemistry letters.

Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.

Mark B. Anderson, G. Paderes, D. Luthin, 2002, Bioorganic & medicinal chemistry letters.

Therapeutic Protein Drug–Drug Interactions

Steven W. Martin, E. Kraynov, 2017 .

Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper

Jane R Kenny, Eugenia Kraynov, Lei Zhang, 2013, Drug Metabolism and Disposition.

Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics

M. Dowty, E. Kraynov, O. Fahmi, 2012 .

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

D. Knighton, J. Lamerdin, J. Christensen, 2010, Proceedings of the National Academy of Sciences.

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.

D. Bouzida, J. Christensen, R. Kania, 2012, Journal of medicinal chemistry.

A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics

P. Vicini, T. Hickling, Xiaoying Chen, 2013, The AAPS Journal.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

E. Kraynov, S. Bergqvist, Joseph H. Lee, 2012, Journal of Experimental & Clinical Cancer Research.

An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity

M. Dorywalska, K. Ching, L. Mosyak, 2021, Cancer Immunology Research.

Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody

S. Youssef, A. Rajpal, C. Dillon, 2020, Molecular Cancer Therapeutics.

Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies

Paolo Vicini, Wei-Zhu Zhong, Kenneth T. Luu, 2013, The AAPS Journal.

Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry

E. Kraynov, Jiang Wu, B. Bates, 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

E. Kraynov, S. Bergqvist, Joseph H. Lee, 2012, Journal of experimental & clinical cancer research : CR.

DMD052225 1598..1609

R. Evers, J. G. Slatter, E. Kraynov, 2013 .

Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.

K. Gajiwala, P. Wei, Jennifer Yang, 2013, Cancer letters.

Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development.

C. Bowman, G. Cappon, E. Kraynov, 2015, Regulatory toxicology and pharmacology : RTP.

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

J. Chaparro-Riggers, L. Aschenbrenner, P. Strop, 2019, Scientific Reports.

Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Mark B. Anderson, G. Paderes, D. Luthin, 2006, Journal of medicinal chemistry.